ecancermedicalscience

Review

Treatment of early-stage HER2 breast cancer—an evolving field

16 Apr 2015
Arlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho

The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2 tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.

Related Articles

Cassio Murilo Hidalgo Filho, Mateus Marinho Nogueira Soares, Wesley Antonio Lopes de Lima, Laura Testa, Marcela Simonis Martins Ferrari, Renata Colombo Bonadio
Badira Cheriyalinkal Parambil, Girish Chinnaswamy, Maya Prasad, Venkata Rama Mohan Gollamudi, Ajay Puri, Ashish Gulia, Sajid Qureshi, Prakash Nayak, Manish Pruthi, Siddhartha Laskar, Nehal Khanna, Jifmi Jose Manjali, Amit Janu, Sneha Shah, Nilendu Purandare, Mukta Ramadwar, Poonam Panjwani, Bharat Rekhi, Pallavi Rane, Shripad Banavali
Elias Zonana-Schatz, Jenniffer Ann-Swain, Jenny Naomi Shiraishi-Piña, Marcos Cherem-Kibrit, José Rodrigo Espinosa
Swasthik Upadhya, Sameer Rastogi, Adarsh Barwad, Shamim Ahmed Shamim, Dikhra Khan, Sudheer Arava, Vineeta Ojha, Akshit Kumar Ganesan Karthikeyan, Akshya Kumar Bisoi
Aditya Dhanawat, Debdeep Samaddar, Bhagyashri Jadhav, Atul Tiwari, Kunal Jobanputra, Arnav Tongaonkar, Minit Jalan Shah, Nandini Menon, Priyamvada Maitre, Mahendra Pal, Amandeep Arora, Aparna Ringe, Archi Agrawal, Santosh Menon, Gagan Prakash, Vedang Murthy, Vanita Noronha, Kumar Prabhash, Amit Joshi